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Naturally occurring polymers such as alginate (AL) and chitosan (CS) are widely used in
biomedical and pharmaceutical fields in various forms such as nanoparticles, capsules,
and emulsions. These polymers have attractive applications in drug delivery because of
their biodegradability, biocompatibility, and nontoxic nature. The pharmaceutical appli-
cations of essential oils such as turmeric oil and lemongrass oil are well-known, and their
active components, ar-turmerone and citral, respectively, are known for their antibacterial,
antifungal, antioxidant, antimutagenic, and anticarcinogenic properties. However, these
essential oils are unstable, volatile, and insoluble in water, which limits their use for new
formulations. Therefore, this study focuses on developing a CSeAL nanocarrier for the
encapsulation of essential oils. The effects of process parameters such as the effect of heat
and the concentrations of AL and CS were investigated. Various physicochemical charac-
terization techniques such as scanning electron microscopy, Fourier transform infrared
spectroscopy, and ultravioletevisible spectroscopy were performed. Results of character-
ization studies showed that 0.3 mg/mL AL and 0.6 mg/mL CS produced minimum-sized
particles (<300 nm) with good stability. It was also confirmed that the oil-loaded nano-
capsules were hemocompatible, suggesting their use for future biomedical and pharma-
ceutical applications. Furthermore, the antiproliferative activity of turmeric oil- and
lemongrass oil-loaded nanocapsules was estimated using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay in A549 cell lines and it was found that both the
nanoformulations had significant antiproliferative properties than the bare oil.
Copyright © 2015, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC.
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Nanotechnology, a boon to health care, involves advances in
medicine, robotics, cosmetics, communication, and genomicshnology and Advanced
anjavur 613401, Tamil N
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ministration, Taiwan. Publ[1e3]. Applications of nanoscience and nanotechnology in
health care led to the genesis of a new field called nanomedicine
[4,5]. At present, nanomedicine makes use of nanomaterials
such as nanoshell, nanobiosensor, nanovaccines, nanorobots,
and nanocapsules for various applications such as diagnosis,Biomaterials (CeNTAB), School of Chemical and Biotechnology,
adu, India.
ished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
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contrast enhancers, detection of pathogens, and other
biomedical applications [6]. Nanotechnology in drug-delivery
system provides an opportunity to deliver drugs for a pro-
longed timewith natural affinity [7]. Nanoparticulate systems,
dendrimers, micelles, liposomes, and nanoemulsions are
some of the nanocarrier systemswidely used in drug delivery.
These nanocarrier systems help in improving biodistribution
of drugs and solubility of hydrophobic compounds, as well as
increasing the bioavailability, reducing the number of doses,
improving drug targeting, and minimizing toxicity, etc.
Among themany nanocarriers, alginate (AL) and chitosan (CS)
have gained more attention due to their biocompatibility,
biodegradability, mucoadhesiveness, and longer in vivo cir-
culation time [8e10]. AL is a negatively charged, Food and
Drug Administration-approved, naturally occurring poly-
saccharide consisting of D-mannuronic acid and L-guluronic
acid arranged as blocks in the polymeric chain. They are
known to undergo proton-catalyzed hydrolysis that is
dependent on pH and temperature [11]. It is known that at low
pH, alginic acid forms an insoluble AL skin, which prevents
the release of encapsulatedmaterial. However, at higher pH, it
becomes a soluble viscous layer, releasing the encapsulated
material [12]. By contrast, CS is a positively charged linear co-
polymer polysaccharide consisting of D-glucosamine and N-
acetyl-D-glucosamine with reactive amino and hydroxyl
groups [13]. CS is prepared from chitin by deacetylation of
chitin using alkaline solutions [14]. It is soluble at low pH but
insoluble at high pH [15e17] and has a unique property called
the permeation enhancing effect, which makes it a good carrier
system. It increases permeation by opening epithelial tight
junctions, which is important for the movement of hydro-
philic compounds [12]. CS being cationic and AL being anionic
make a good polyelectrolyte complex (PEC) [18]. The formation
of PEC is known to be influenced by various factors such as pH,
molecular weight of the polymers, and the ratio of AL to CS
[19,20]. Positive aspects of CSeAL PEC have favored its use as a
drug-carrier system [8,21,22].
Essential oils are volatile, aromatic liquids obtained from
plants with therapeutic activities. They are widely used in food
flavoring agents, perfumes, and pharmaceutical drugs [23,24].
Of the many essential oils, turmeric oil and lemongrass oil are
known for their high therapeutic potential. Turmeric belongs to
the family Zingiberaceae. Traditionally, it is used for the treat-
ment of sprains, superficial wounds, cough, and fungal in-
fections. Both turmeric and its modified essential oil forms are
known to havemany therapeutic properties such as anticancer
[23,25], antifungal [26], antioxidant [27], anti-inflammatory [28],
and antimutagenic [29] effects. Ar-turmerone, a major ingre-
dient of turmeric oil is well-known for its antimutagenic, anti-
platelet, and antifungal properties [30,31]. Lemongrass belongs
to the family Poaceae. It cools down body temperature, rheu-
matisms, muscle cramps, and many gastrointestinal disorders
[32]. Some of the therapeutic properties of lemongrass oil
include anti-inflammatory [33], antimicrobial [34], anticancer
[35], and antiproliferative [36] actions. The major ingredient of
lemongrass oil is citral, which is also known for its antifungal,
anticancer, antiproliferative, and anticlastogenic properties
[37]. However, turmeric oil and lemongrass oil have poor
physical properties such as hydrophobicity, susceptible todegradation, and volatility, making them difficult to be used in
pharmaceutical applications [30,31,38]. These disadvantages
can be overcome to an extent by encapsulating these essential
oils in a nanocarrier. There are several potential advantages of
conjugating anticancer agents with nanoparticles, including
targeted delivery and controlled release at diseased sites by
changing their pharmacokinetic profile [39,40].
Therefore, in this work, formulation of CSeAL nano-
capsules was carried out with the goal of enhancing the
physical stability of both the essential oils by encapsulating
them into the nanocapsules.2. Materials and methods
2.1. Chemicals
Sodium AL and CS (degree of acetylation  75%) were pur-
chased from HiMedia Laboratories (Mumbai, Maharashtra,
India). Commercially available turmeric oil (Curcuma longa)
and lemongrass oil (Cymbopogon citratus) were purchased from
AOS Products Private Limited (New Delhi, India). Thiazolyl
blue tetrazolium bromide was purchased from Sigma-Aldrich
(Bangalore, Karnataka, India). Human lung adenocarcinoma
epithelial cell line (A549) was obtained from the National
Centre for Cell Science (Pune, Maharashtra, India). The F-12K
1 nutrient mixture (Kaighn's modified medium), fetal bovine
serum, EDTAetrypsin 0.05%, Dulbecco's phosphate-buffered
saline 1, and penicillinestreptomycin were procured from
Invitrogen (Bangalore, Karnataka, India). Calcium chloride
and other solvents used in this study were of analytical grade.
The experiments were performed using deionized distilled
water and were carried out in triplicates.
2.2. Maintenance of cell culture
Human lung adenocarcinoma epithelial cells (A549) were
cultured in F-12K (Kaighn's) medium containing 10% fetal
bovine serum, 100 U/mL penicillinestreptomycin at 37C in a
5% CO2 humidified atmosphere.
2.3. Preparation of essential oil-loaded CSeAL
nanocapsules
Emulsification processes are used generally in the preparation
of nanocapsules as well as in other food, cosmetic, and
chemical industries [41]. Essential oil-loaded CSeAL nano-
capsules were prepared using the method suggested by Lert-
sutthiwong et al [30], but with somemodifications. In brief, the
oil in water nanoemulsion was prepared by adding 20 mL
aqueous AL solution of various concentrations (0.3 and 0.6mg/
mL) to 1% (w/v) Tween-80. The pH of aqueous AL solution was
maintained between 5 and 5.5 to obtain nano-sized capsules.
Subsequently, 0.6mL of ethanolic turmeric oil solution (20mg/
mL) was added dropwise into this mixture. Following 15 mi-
nutes of sonication, 4 mL of 0.67 mg/mL calcium chloride
(CaCl2) solutionwas added and the emulsionwas stirred for 30
minutes. The emulsion was then combined with 4 mL of CS
solution of various concentration [0.3 or 0.6 mg/mL in 1% (v/v)
acetic acid] and stirred for the next 30 minutes. The pH of CS
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sion was equilibrated overnight and solvent removal was
achieved by rotary evaporation at 40C for 20 minutes.
Lemongrass oil-loaded nanocapsules were also synthesized
using the same protocol.
2.4. Optimization of process parameters
Various parameters were altered to understand the factors
involved in the preparation of nanocapsules. Optimization of
essential oil-loaded CSeAL nanocapsules was achieved by
varying the concentrations of CS (0.6 or 0.3mg/mL) and AL (0.6
or 0.3 mg/mL) and by varying the effect of heating the AL so-
lution prior usage for removal of any impurity before use.
Furthermore, physicochemical characterization was per-
formed to choose the best parameters for the essential oil-
loaded nanocapsules.
2.5. Physicochemical characterization of nanocapsules
2.5.1. Particle size and zeta potential
The hydrodynamic size and zeta potential of nanocapsules
were determined by Malvern Zetasizer 3000HS (Malvern In-
struments Ltd., UK). Zeta potential provides information
about the potential difference between the dispersion me-
dium and the stationary layer of the fluid attached to the
dispersed particle, which helps to know about the stability of
the nanoformulations. Measurements were made using
aqueous diluted samples (2:1 ratio). Using the principle of
photon correlation spectrometry, this instrument also gives
the measurement of particle-size distributions in the range
between 200 and 500 nm.
2.5.2. Scanning electron microscopy
The surface morphology and shape of various nanomaterials
and medical and biological samples can be obtained with a
field emission scanning electron microscope (JSM-6360, JEOL,
Japan) at 15 kV. Approximately 5 mL of the sample was freeze
dried and imaged using the scanning electron microscope.
2.5.3. Fourier transform infrared spectroscopy
Oscillations of atoms in molecules were measured by infrared
(IR) and Raman spectroscopy. These vibrational spectros-
copies provide details about molecular vibrational energy
levels. These energy levels are directly proportional to mo-
lecular structure, intermolecular interaction, and the chemi-
cal bonding [42]. The Fourier transform infrared (FT-IR)
spectra of nanoformulations were examined using KBr pellet
[1% (w/w) of product in KBr] with a resolution of 4 cm1 and
100 scans/sample on Perkin Elmer Spectrum RXI FT-IR spec-
trophotometer. It is a powerful tool for identifying different
types of chemical bonds in a molecule by producing an
infrared absorption spectrum. The FT-IR spectra of essential
oil, bare CSeAL nanocapsules, and essential oil-loaded CSeAL
nanocapsules were collected between 4000 and 800 cm1.
2.5.4. Encapsulation efficiency of essential oil-loaded
nanocapsules
To determine their encapsulation efficiency (EE%), nano-
capsules were first separated by centrifugation (6000 rpm) at4C for 10 minutes from the aqueous medium containing
nonassociated oil. The supernatant was removed and 3 mL of
methanol was added to the pellet, vortexed well, and centri-
fuged for another 30 minutes. The supernatant was collected
and quantified spectrophotometrically. Using a standard
curve that was plotted using different concentrations of oil,
the concentration of the unknown oil was estimated. The oil
EE% of the nanocapsules was calculated using the following
equation:
Encapsulation efficiency (%)¼ [(Total amount of oil Free oil)/
Total amount of oil]  100]
2.5.5. In vitro release studies
An in vitro release study was performed using the dialysis
method. In brief, the dialysis bag was soaked in distilled water
to remove the preservatives and rinsed with phosphate-
buffered saline (PBS) solution. The essential oil-loaded nano-
capsules were redispersed in 3 mL of PBS solution and loaded
into the dialysis bag, surrounded by 50 mL of PBS containing
20% ethanol at pH 1.5 and 7.4. The use of ethanol helps to
minimize aggregation and release oil more uniformly [43]. The
time-dependent release study at 0e12 hours was performed.
All sets were incubated at 37C under gentle agitation. At
definite time intervals, 3 mL of the mediumwas removed and
was replaced with fresh medium and quantified spectropho-
tometrically. The release was quantified as follows:
Release (%) ¼ [Released oil/Total oil]  100
2.5.6. Hemocompatibility assay
The hemocompatibility of essential oil-loaded nanocapsules
can be understood by the hemolysis test. Blood was drawn
from a healthy human volunteer, with informed consent, to a
tube containing anticoagulant solution of EDTA and incubated
with 0.9% saline at 37C. Essential oil-loaded nanocapsules
were added to diluted blood and incubated for 60 minutes at
37C. Blood with distilled water was taken as the positive
control and 0.9% saline with blood was taken as the negative
control. Samples were centrifuged at 3000 rpm for 5 minutes
after incubation.
2.5.7. Cell viability assay
The antiproliferative activity of the cancer cells was observed
using yellow tetrazolium dye, which is reduced to purple
formazan in live cells. These formazan crystals can then be
dissolved using PBS and quantified using a spectrophotometer
(1420-040 VICTOR3 multilabel counter, PerkinElmer, USA) at
490 nm. An increase in purple color directly contributes to the
increase in the number of cells. Cells were seeded into 96-well
plate 24 hours before the treatment. In brief, the cells were
exposed to oil-loaded nanocapsules, free oil (dissolved in
ethanol), and bare nanocapsules. The relative viability was
expressed as a percentage of the control well that was treated
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of the absorbance of treated cell (Nt) to the absorbance of
untreated cells (Nu) multiplied by 100.
Cell viability (%) ¼ (Nt/Nu)  100
3. Results and discussion
3.1. Size and stability of nanocapsules
Essential oil-loaded nanocapsules were prepared using the
ionic gelation method. Calcium chloride was used as a
crosslinker and ethanol was used to dilute the oil. Particle size
and stability was analyzed using the zetasizer. The following
three parameters were considered: heating of AL solution and
concentrations of AL and CS. Initially, the concentration of CS
was kept constant and the concentration of AL was varied. For
every concentration, the effect of heat was also observed
(Tables 1 and 2). In general, zeta potential values less than
30 mV and þ30 mV are considered stable. Considering both
particle size and stability, it was observed that the combina-
tion of 0.3 mg/mL AL and 0.6 mg/mL CS produced best results
with particle sizes of 256 and 226 nm for turmeric oil- and
lemongrass oil-loaded nanocapsules, respectively. The zeta
potential was greater than þ35 mV in both oil-loaded parti-
cles, indicating their good stability.
However, consistent differences in particle size or zeta
potential were not revealed due to the heating of AL solutions
before the preparation process. Thereafter, heating of AL so-
lutions was not performed. A better size than previous reports
[18] was achieved mostly due to maintenance of pH of AL
(5e5.3) and CS (4.5e5) solutions [44]. Within this pH, the
carboxyl groups were ionized in AL and the amine groups
were protonated in CS, which had a major contribution to the
formation of complex and optimal interaction for the forma-
tion of smaller nanocapsules. Therefore, the concentration of
the polymers was optimized and the same concentration was
used for further physicochemical characterization studies.3.2. Encapsulation efficiency
The EE% was determined using ultravioletevisible spectros-
copy. Using a standard graph (y ¼ 0.044x þ 0.030, R2 ¼ 0.991)
and (y ¼ 0.0772x þ 2.5194, R2 ¼ 0.9846), the concentrations ofTable 1 e Optimization of process parameters for the encapsu
Concentration
of alginate
(mg/mL)
Concentration
of chitosan
(mg/mL)
With heating
Turmeric oil Lem
Particle
size (nm)
Zeta
potential
(mV)
Particl
size (nm
0.3 0.6 363.5 45.5 405.3
0.6 0.6 399.1 40.6 702.1
Bold values indicate the optimized values.the unknown turmeric oil and lemongrass oil were deter-
mined, respectively. Samples were analyzed in triplicates and
it was found that 71.1% of the total turmeric oil and 86.9% of
the lemongrass oil were encapsulated into the nanocapsules.
This suggests that our carrier is very well suited for encap-
sulation of hydrophobic drugs.3.3. FT-IR analysis
To support the results of zeta potential and EE% of nano-
capsules, further studies were carried out by FT-IR analysis to
know about the complex formation and interaction of major
functional groups involved in the encapsulation of essential
oil (Figs. 1A and B and 2A and B). These results helped us in
confirming the presence of oil in our nanocapsules. The
spectra of bare nanocapsules clearly revealed that the amino
groups of CS and the carboxyl groups of AL interact together to
form the strong PEC [21]. The peaks at 3428 cm1 indicate the
presence of hydroxyl and amino groups from AL and CS [45].
The peak at 1622.38 cm1 of blank CSeAL nanocapsules in-
dicates the association of the carboxylate group of AL with CS
[46] and the peak at 1080 cm1 indicates the amino group of
CS. It is also evident that the major peaks present in the
spectra of bare nanocapsules are also prominent in the loaded
nanocapsules. This indicates the strong interaction between
CS and AL in oil-loaded nanocapsules.
However, there are many minor peaks and some major
peaks, which are formed due to the presence of essential oil as
shown in Figs. 1B and 2B. In the case of turmeric oil-loaded
nanocapsules, the peak at 1734 cm1 in Fig. 2B corresponds
to the 1714 cm1 peak present in Fig. 1A and indicates the
presence of C¼O groups probably from the active component,
turmerones [47]. Similarly, the peak at 1736 cm1 in Fig. 2B also
corresponds to the peak at 1722 cm1 in Fig. 2A, indicating the
presence of citral, a highly therapeutic compound in lemon-
grass oil. The shift in the peaks indicates the possible inter-
action and successful encapsulation of oil into the carrier.
Major peaks at 3429, 2923, 1625, and 1099 cm1 in turmeric oil-
loaded nanocapsules and at 3428, 2924, 1622, and 1080 cm1 in
lemongrass oil-loaded nanocapsules indicate the presence of
NeH, OeH, C¼O, and CHeOH functional groups, respectively.3.4. Scanning electron microscopy
To obtain information about the morphology of the turmeric
oil- and lemongrass oil-loaded nanocapsules, scanning elec-
tron microscopy (SEM) analysis was performed. SEM analysislation of turmeric oil and lemongrass oil.
Without heating
ongrass oil Turmeric oil Lemongrass oil
e
)
Zeta
potential
(mV)
Particle
size (nm)
Zeta
potential
(mV)
Particle
size (nm)
Zeta
potential
(mV)
38.8 256.6 37.3 226.4 35.7
38.2 895.5 21.3 786.6 40.6
Table 2 e Optimization of ratios of alginate and chitosan.
Concentration of
alginate (mg/mL)
Concentration of
chitosan (mg/mL)
Turmeric oil Lemongrass oil
Particle size (nm) Zeta potential (mV) Particle size (nm) Zeta potential (mV)
0.3 0.6 256.6 37.3 226.4 35.7
0.3 0.3 92.37 27.0 59.34 11.8
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capsules. It can be inferred fromFig. 3A andB that the essential
oil-loaded nanocapsules have spherical surface morphology
and their mean size was found to be below 300 nm.Fig. 1 e Fourier transform infrared spectra: (A) turm
Fig. 2 e Fourier transform infrared spectra: (A) lemong3.5. In vitro release study
Fig. 4 indicates the release of both the essential oil-loaded
CSeAL nanocapsules at pH 7.4 and 1.5. It was observed thateric oil; (B) turmeric oil-loaded nanocapsules.
rass oil; (B) lemongrass oil-loaded nanocapsules.
Fig. 3 e Scanning electron microscopic images: (A) turmeric oil-loaded nanocapsules; (B) lemongrass oil-loaded
nanocapsules.
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At pH 7.4, approximately 90% of the encapsulated turmeric oil
was released, whereas only 42% of the encapsulated lemon-
grass oil was released for a period of 48 hours. At pH 1.5, the
release was less than 70% and 38% for both the encapsulated
turmeric oil and lemongrass oil, respectively (Fig. 4A and B).
This might be attributed to the formation of insoluble alginic
skin at acidic pH. This suggests that the drug release of CSeAL
nanoparticles is pH sensitive and more of the oil will be
released in the blood system (at pH 7.4) than in the acidic
stomach (at pH 1.5). Therefore,more of the oil will be absorbed
into the blood system and in turn transported in the blood
circulatory system to the site of infectionmore efficiently than
when the oil is not encapsulated in the nanoparticles.3.6. Hemocompatibility
Both the essential oil-loaded nanocapsules were incubated
with blood samples and the results were observed. The ob-
tained image clearly demonstrates that there was no lysis in
the supernatant and the red blood cells settled down as pel-
lets. Absence of lysis in the incubated sample demonstrated
that this formulation was perfectly suitable for circulation in
blood (Fig. 5A and B). Distilled water was used as the positiveFig. 4 e Essential oil release kinetics. Drug-release profile of (A)
Lemongrass oil-loaded nanocapsules at pH 7.4 and 1.5.control to produce lysis of red blood cells, which contributes to
the red supernatant. Saline, which is used as the negative
control, did not show any hemolysis or toxicity to red blood
cells, and therefore, the percentage of lysis is 0, whereas it is
100 for distilled water. The blood samples incubated with oil-
loaded nanocapsules showed results similar to those of saline,
and therefore, it can be concluded that they have 0% hemo-
lysis. Thus, it is proved that both turmeric oil- and lemongrass
oil-loaded nanocapsules were hemocompatible and could be
suitable for further drug-delivery applications.3.7. Cell viability assay
The antiproliferative effect of both turmeric oil- and lemon-
grass oil-loaded nanocapsules was evaluated using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay. In brief, cultured A549 cells were exposed to
carrier alone, free oil, and encapsulated oil at various con-
centrations (0.4 and 0.2 mg/mL) for 24 hours. To find the
viability of cells, MTT reagent (thiazolyl blue tetrazolium
bromide) was added to all the wells and incubated for 24
hours. As a result, formazan crystals were dissolved using PBS
solution and the absorbance was noted using a
spectrophotometer.turmeric oil-loaded nanocapsules at pH 7.4 and 1.5. (B)
Fig. 5 e Hemolysis assay. Hemocompatibility of (A) turmeric oil-loaded nanocapsules; (B) lemongrass oil-loaded
nanocapsules. LGO ¼ lemongrass oil; NC ¼ negative control; PC ¼ positive control; TO ¼ turmeric oil.
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cancer cell viability. When treated with 0.4 mg/mL turmeric
oil-loaded CSeAL nanocapsules, there was about 40% decline
in viability. At a lesser concentration (0.2 mg/mL turmeric oil-
loaded nanocapsules), the treated cells showed 31% decline in
cancer cell viability. By contrast, at the same concentration,
lemongrass oil-loaded nanocapsules showed toxic effects
with activity of 20% and 17% for 0.4 and 0.2 mg/mL concen-
trations, respectively (Fig. 6A and B). Concentration-
dependent cell viability was observed in both free and
encapsulated oil. Compared with lemongrass oil, turmeric oil
showed a high level of inhibition in cell viability. Thismight be
attributed to the presence of various powerful anticancer
components (turmerone), which were responsible for reduc-
tion in cancer cell viability. This has led the path for turmeric
oil and its components to be tested in various clinical trials.Fig. 6 e Cytotoxicity of essential oil-loaded nanocapsules in A5
diphenyltetrazolium bromide assay: (A) turmeric oil; (B) lemongFree oil of both the concentrations showed less than 10%
toxic activity. Thismay be due to the fact that encapsulated oil
could reach to individual cells and deliver the oil to them.
However, it was not possible for the free oil to reach the cells
individually owing to its hydrophobicity. The nontoxic nature
of carrier was confirmed with the viability of treated cells,
whichwas 98%. Higher loading of turmeric oil was expected to
increase toxic activity and our carrier was very well suited for
these kinds of drug-delivery applications, which were also
supported by our hemocompatibility results.4. Conclusion
CSeAL nanocapsules were synthesized using an ionic gelation
method and the size of the particles was below 300 nm with49 cells using 3-(4,5-dimethylthiazol-2-yl)-2,5-
rass oil.
j o u r n a l o f f o o d and d ru g an a l y s i s 2 3 ( 2 0 1 5 ) 5 6 0e5 6 8 567good stability. SEM results suggest that the morphology of
both the essential oil-loaded nanocapsules was spherical. EE%
was found to be 71% and 86.9% for turmeric oil- and lemon-
grass oil-loaded nanocapsules, respectively. FT-IR results
showed the functional groups, which played a role in the
interaction. The drug-release profile showed a slow and sus-
tained release at neutral pH for 48 hours. The antiproliferative
activity of essential oil-loaded nanocapsules was estimated
usingMTT assay and it was found that the activity of turmeric
oil is retained in the carrier. The carrier showed high cell
viability percentage, which indicates that it is nontoxic. It was
also confirmed from the clear supernatant in hemolysis assay
that our oil-loaded nanocapsules were hemocompatible,
which suggests that they are a suitable carrier for further
biomedical applications.Conflicts of interest
All contributing authors declare no conflicts of interest.
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